Articles tagged with Binding Proteins
Researchers discovered that certain antibodies employ unusual tactics to block bacterial adhesion, including creating molecular wedges and conformational traps. These mechanisms could lead to the development of immune therapies targeting glycan-binding cell-attachment proteins produced by bacteria causing urinary tract infections.
A Kobe University team identified the cause of pollutant accumulation in pumpkins and their relatives, discovering that specific proteins bind to pollutants and transport them through the plant. By controlling these proteins' behavior, safer crops can be created and polluted soils can be cleaned.
Researchers found that a faster rate of binding does not always translate to greater potency, as the study's lead author David Heppner explained. The team proposed a two-step design process balancing inactivation efficiency rates with target selectivity and other parameters to identify promising compounds.
Researchers have made significant discoveries about the role of GP38 in viral infections and pathogenesis, highlighting its potential as a target for vaccines and medical countermeasures. Non-neutralizing GP38-specific antibodies have shown protective efficacy against lethal challenge, reducing circulating GP38 and vascular leak.
A study identified a protein called IL-22BP that affects the composition of gut microbiota and the body's response to bacterial infection. The absence of this protein results in stronger defenses against intestinal infections, including increased production of short-chain fatty acids that promote an anti-inflammatory environment.
Researchers have identified the first inhibitors of the cancer-related RNA-modifier METTL16, which prevent its interaction with RNA. This breakthrough lays the foundation for novel RNA-targeting therapeutics and better investigation of METTL16's role in disease and health.
A team of researchers from Texas Heart Institute and Baylor College of Medicine have made a significant discovery about the underlying molecular cell states within transplanted pediatric hearts. They found that donor-derived tissue-resident macrophages are crucial for graft acceptance, but their loss leads to allograft failure.
Researchers have found a way to control MYC's hyperactivity using a peptide compound with sub-micro-molar affinity. This breakthrough offers hope for more effective treatments for cancer patients.
Researchers at Texas A&M University engineered DARPins to block the interaction between the COVID-19 virus and host cells, significantly reducing disease progression. The nasal sprays showed effectiveness against various variants, including omicron, and could provide a lower-cost therapeutic option for those at high risk.
Researchers at ETH Zurich have created synthetic phages that can recognize and attack a broader range of bacterial strains, providing a potential solution for treating antibiotic-resistant infections. The synthesized phages share the same genome but have different receptor binding proteins, allowing them to target specific hosts.
Research found that carbohydrate-binding protein Gal-1 modified infection in heart muscle cells, highlighting its importance in response to parasite infection. Galectins, like Gal-1, play a role in regulating parasite interactions and may recognize glycans on the host cell surface used for invasion.
Researchers from Ghent University have developed a new rice prototype with stable folate content, which remains effective upon long-term storage. This breakthrough can offer a solution to health problems related to folate deficiency in developing countries.
A new study published in Neural Regeneration Research suggests that X-linked methyl-CpG binding protein 2 (MeCP2) may be a promising therapeutic target for treating Parkinson's disease. Researchers found that overexpressing MeCP2 in damaged human cells reduced apoptosis and increased tyrosine hydroxylase levels, indicating potential be...
Researchers isolated a nerve toxin from an ocean-dwelling snail that may enable scientists to develop medications for a range of nervous system disorders. The new toxin fits like a key into specific lock-like receptors in the brain, opening up potential for designing new medicines.
Researchers at Max Planck Institute of Experimental Medicine discovered a molecular switch in CRF by replacing a single amino acid, allowing for the development of selective CRF-like agonists and antagonists. This breakthrough has potential applications in treating anxiety disorders.